|
1
|
Zhu RX, Seto WK, Lai CL and Yuen MF:
Epidemiology of hepatocellular carcinoma in the Asia-pacific
region. Gut Liver. 10:332–339. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM: Updated treatment approach to
hepatocellular carcinoma. J Gastroenterol. 40:225–235. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buggy DJ and Smith G: Epidural anesthesia
and analgesia: Better outcome after major surgery? Growing evidence
suggests so. BMJ. 319:530–531. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ogawa K, Hirai M, Katsube T, Murayama M,
Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T and Kajiwara T:
Suppression of cellular immunity by surgical stress. Surgery.
127:329–336. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ben-Eliyahu S: The price of anticancer
intervention. Does surgery promote metastasis? Lancet Oncol.
3:578–579. 2002.PubMed/NCBI
|
|
6
|
Ben-Eliyahu S, Page GG, Yirmiya R and
Shakhar G: Evidence that stress and surgical interventions promote
tumor development by suppressing natural killer cell activity. Int
J Cancer. 80:880–888. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deiner S and Silverstein JH: Long-term
outcomes in elderly surgical patients. Mt Sinai J Med. 79:95–106.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deflandre E and Lacroix S: It is time for
anesthetists to act as perioperative physicians. Minerva
Anestesiol. 82:257–258. 2016.PubMed/NCBI
|
|
9
|
Martin TA, Ye L, Sanders AJ, Lane J and
Jiang WG: Cancer invasion and metastasis: Molecular and cellular
perspectiveMetastatic Cancer Clinical Biological Perspectives 2013.
Jandial R: Landes Bioscience; Austin, TX: pp. 135–168. 2013
|
|
10
|
Tsuchiya Y, Sawada S, Yoshioka I, Ohashi
Y, Matsuo M, Harimaya Y, Tsukada K and Saiki I: Increased surgical
stress promotes tumor metastasis. Surgery. 133:547–555. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ucuzian AA, Gassman AA, East AT and
Greisler HP: Molecular mediators of angiogenesis. J Burn Care Res.
31:158–175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Distler JH, Hirth A, Kurowska-Stolarska M,
Gay RE, Gay S and Distler O: Angiogenic and angiostatic factors in
the molecular control of angiogenesis. Q J Nucl Med. 47:149–161.
2003.PubMed/NCBI
|
|
13
|
Simons M: Integrative signaling in
angiogenesis. Mol Cell Biochem. 264:99–102. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Z and Han ZC: STAT3: A critical
transcription activator in angiogenesis. Med Res Rev. 28:185–200.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoeben A, Landuyt B, Highley MS, Wildiers
H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth
factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Senger DR, Galli SJ, Dvorak AM, Perruzzi
CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid.
Science. 219:983–985. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F,
Sawaya R and Huang S: Stat3 activation regulates the expression of
matrix metalloproteinase-2 and tumor invasion and metastasis.
Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu
M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3
in human melanoma promotes brain metastasis. Cancer Res.
66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Exadaktylos AK, Buggy DJ, Moriarty DC,
Mascha E and Sessler DI: Can anesthetic technique for primary
breast cancer surgery affect recurrence or metastasis?
Anesthesiology. 105:660–664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bauer M, Rensing H and Ziegenfuss T:
Anesthesia and perioperative immune function. Anaesthesist.
47:538–556. 1998.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borsook D, George E, Kussman B and Becerra
L: Anesthesia and perioperative stress: Consequences on neural
networks and postoperative behaviors. Prog Neurobiol. 92:601–612.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marshall L, Khan AH and Buggy DJ: Can
anaesthetic and analgesic techniques for cancer surgery affect
cancer recurrence and metastasis? Curr Anesthesiology Rep.
5:190–202. 2015. View Article : Google Scholar
|
|
24
|
Vahabi S and Eatemadi A: Effects of
anesthetic and analgesic techniques on cancer metastasis. Biomed
Pharmacother. 87:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ogren SO and Holm AC: Test-specific
effects of the 5-HT reuptake inhibitors alaproclate and zimelidine
on pain sensitivity and morphine analgesia. J Neural Transm.
47:253–271. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sacerdote P, Bianchi M, Gaspani L,
Manfredi B, Maucione A, Terno G, Ammatuna M and Panerai AE: The
effects of tramadol and morphine on immune responses and pain after
surgery in cancer patients. Anesth Analg. 90:1411–1414. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yeager MP, Colacchio TA, Yu CT,
Hildebrandt L, Howell AL, Weiss J and Guyre PM: Morphine inhibits
spontaneous and cytokine-enhanced natural killer cell cytotoxicity
in volunteers. Anesthesiology. 83:500–508. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sasamura T, Nakamura S, Iida Y, Fujii H,
Murata J, Saiki I, Nojima H and Kuraishi Y: Morphine analgesia
suppresses tumor growth and metastasis in a mouse model of cancer
pain produced by orthotopic tumor inoculation. Eur J Pharmacol.
441:185–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ash SA and Buggy DJ: Does regional
anaesthesia and analgesia or opioid analgesia influence recurrence
after primary cancer surgery? An update of available evidence. Best
Pract Res Clin Anaesthesiol. 27:441–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gupta K, Kshirsagar S, Chang L, Schwartz
R, Law PY, Yee D and Hebbel RP: Morphine stimulates angiogenesis by
activating proangiogenic and survival-promoting signaling and
promotes breast tumor growth. Cancer Res. 62:4491–4498.
2002.PubMed/NCBI
|
|
31
|
Cao LH, Li HT, Lin WQ, Tan HY, Xie L,
Zhong ZJ and Zhou JH: Morphine, a potential antagonist of cisplatin
cytotoxicity, inhibits cisplatin-induced apoptosis and suppression
of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep.
6:187062016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rahaman SO, Vogelbaum MA and Haque SJ:
Aberrant Stat3 signaling by interleukin-4 in malignant glioma
cells: Involvement of IL-13Ralpha2. Cancer Res. 65:2956–2963. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lamprecht B, Kreher S, Anagnostopoulos I,
Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B and
Mathas S: Aberrant expression of the Th2 cytokine IL-21 in Hodgkin
lymphoma cells regulates STAT3 signaling and attracts Treg cells
via regulation of MIP-3alpha. Blood. 112:3339–3347. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yue P, Zhang X, Paladino D, Sengupta B,
Ahmad S, Holloway RW, Ingersoll SB and Turkson J: Hyperactive EGF
receptor, Jaks and Stat3 signaling promote enhanced colony-forming
ability, motility and migration of cisplatin-resistant ovarian
cancer cells. Oncogene. 31:2309–2322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ali SM, Wang K, Johnson A, Rodriguez AA,
Elvin JA, Vergilio JA, Suh JH, Chumsri S, Morosini D, Yelensky R,
et al: Abstract P6-03-02: EGFR genomic alterations in 5,605 cases
of refractory and metastatic breast cancer. Cancer Res. 76 Suppl
4:P6–03-02. 2016. View Article : Google Scholar
|
|
37
|
Milagre CS, Gopinathan G, Everitt G,
Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell
DD, Hochhauser D and Balkwill FR: Adaptive upregulation of EGFR
limits attenuation of tumor growth by neutralizing IL6 antibodies,
with implications for combined therapy in ovarian cancer. Cancer
Res. 75:1255–1264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Falchook GS, Naing A, Wheler JJ,
Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F,
Hess KR, et al: Dual EGFR inhibition in combination with anti-VEGF
treatment in colorectal cancer. Oncoscience. 1:540–549. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Engilbertsson H, Aaltonen KE, Björnsson S,
Kristmundsson T, Patschan O, Rydén L and Gudjonsson S:
Transurethral bladder tumor resection can cause seeding of cancer
cells into the bloodstream. J Urol. 193:53–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang W, Liu JN and Tan XY: Vaccination
with xenogeneic tumor endothelial proteins isolated in situ
inhibits tumor angiogenesis and spontaneous metastasis. Int J
Cancer. 125:124–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ramírez MF, Huitink JM and Cata JP:
Perioperative clinical interventions that modify the immune
response in cancer patients. Open J Anesthesiology. 3:133–139.
2013. View Article : Google Scholar
|
|
42
|
Wang X, Cao W, Mo M, Wang W, Wu H and Wang
J: VEGF and cortactin expression are independent predictors of
tumor recurrence following curative resection of gastric cancer. J
Surg Oncol. 102:325–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chavira E, Wilson M, Assaf SA, Ingles SA,
Llanes A and Chmait R: Anti-angiogenic state in twin-twin
transfusion syndrome ameliorated after laser surgery. Ame J Obst
Gynecology. 206:S52. 2012. View Article : Google Scholar
|
|
44
|
Zielinski CE, Mele F, Aschenbrenner D,
Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A and
Sallusto F: Pathogen-induced human TH17 cells produce IFN-γ or
IL-10 and are regulated by IL-1β. Nature. 484:514–518. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
O'Connell J, Bennett MW, O'Sullivan GC,
Collins JK and Shanahan F: The Fas counterattack: Cancer as a site
of immune privilege. Immunol Today. 20:46–52. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Müller CB, De Bastiani MA, Becker M,
França FS, Branco MA, Castro MA and Klamt F: Potential crosstalk
between cofilin-1 and EGFR pathways in cisplatin resistance of
non-small-cell lung cancer. Oncotarget. 6:3531–3539. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg
JF: Mutations in the EGFR kinase domain mediate STAT3 activation
via IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Abbott BD, Buckalew AR, DeVito MJ, Ross D,
Bryant PL and Schmid JE: EGF and TGF-alpha expression influence the
developmental toxicity of TCDD: Dose response and AhR phenotype in
EGF, TGF-alpha, and EGF + TGF-alpha knockout mice. Toxicol Sci.
71:84–95. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weaver CT, Harrington LE, Mangan PR,
Gavrieli M and Murphy KM: Thl7: An effector CD4 T cell lineage with
regulatory T cell ties. Immunity. 24:677–688. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sen B, Saigal B, Parikh N, Gallick G and
Johnson FM: Sustained src inhibition results in signal transducer
and activator of transcription 3 (STAT3) activation and cancer cell
survival via altered Janus-activated kinase-STAT3 binding. Cancer
Res. 69:1958–1965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Juergens RA and Brahmer JR: Adjuvant
treatment in non-small cell lung cancer: Where are we now? J Natl
Compr Canc Netw. 4:595–600. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Smith RA and Glynn TJ: Epidemiology of
lung cancer. Radiol Clin North Am. 38:453–470. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fossella FV, DeVore R, Kerr RN, Crawford
J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al:
Randomized phase III trial of docetaxel versus vinorelbine or
ifosfamide in patients with advanced non-small-cell lung cancer
previously treated with platinum-containing chemotherapy regimens.
The TAX 320 non-small cell lung cancer study group. J Clin Oncol.
18:2354–2362. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Herrera B, van Dinther M, Ten Dijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian
cancer cell proliferation. Cancer Res. 69:9254–9262. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jean GW and Shah SR: Epidermal growth
factor receptor monoclonal antibodies for the treatment of
metastatic colorectal cancer. Pharmacotherapy. 28:742–754. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
57
|
Song JI and Grandis JR: STAT signaling in
head and neck cancer. Oncogene. 19:2489–2495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Morlacchi P, Robertson FM, Klostergaard J
and McMurray JS: Targeting SH2 domains in breast cancer. Future Med
Chem. 6:1909–1926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lapeire L, Hendrix A, Lambein K, Van
Bockstal M, Braems G, Van Den Broecke R, Limame R, Mestdagh P,
Vandesompele J, Vanhove C, et al: Cancer-associated adipose tissue
promotes breast cancer progression by paracrine oncostatin M and
Jak/STAT3 signaling. Cancer Res. 74:6806–6819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Penuel E, Kapp AV, Do A, Tam R, Sumiyoshi
T, Marathe C, Sa S, Peale F, Lackner M, Holden S, et al: Biomarker
evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus
cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell
carcinomas of the head and neck (SCCHN) [MEHGAN]. Cancer Res. 75
Suppl 15:15532015. View Article : Google Scholar
|
|
61
|
Luwor RB, Baradaran B, Taylor LE, Iaria J,
Nheu TV, Amiry N, Hovens CM, Wang B, Kaye AH and Zhu HJ: Targeting
Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor
cells in vitro and in vivo. Oncogene. 32:2433–2441.
2013. View Article : Google Scholar : PubMed/NCBI
|
